Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

54.900
+0.1000.18%
Volume:846.00K
Turnover:46.80M
Market Cap:16.42B
PE:-27.91
High:56.000
Open:53.400
Low:53.100
Close:54.800
52wk High:80.000
52wk Low:31.000
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:0.78
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.967
ROE:-8.82%
ROA:-5.44%
PB:4.56
PE(LYR):-27.91
PS:16.70

Loading ...

Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now

Simply Wall St.
·
Feb 03

Keymed Biosciences Inc. (02162) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 02

Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA

Stock News
·
Jan 27

HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List

Stock News
·
Dec 08, 2025

Keymed Biosciences Inc. (02162) Reports Steady Share Capital for November 2025

Bulletin Express
·
Dec 01, 2025

HK Stock Movement | KEYMED BIO-B (02162) Rises Over 4% as Institutions Bullish on CM512's Global Value; Spesolimab Sales Expected to Accelerate Next Year

Stock News
·
Nov 25, 2025

China Post Securities: Rapid Clinical Progress in Autoimmune Bispecific Antibodies, Sustained Trading and R&D Momentum

Stock News
·
Nov 18, 2025

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12, 2025

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Simply Wall St.
·
Nov 06, 2025

HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints

Stock News
·
Nov 05, 2025

HK Stock Movement | KEYMED BIO-B (02162) Surges Over 7% as Goldman Sachs Highlights Stapokibart's Potential to Establish Valuation Foundation

Stock News
·
Nov 03, 2025

Southbound Capital Flow Statistics (T+2) | November 3

Stock News
·
Nov 03, 2025

HK Stock Connect Shareholding Changes as of October 30

Stock News
·
Oct 30, 2025

Hong Kong Stocks Movement | Pharmaceutical Stocks Continue Multi-Day Decline Amid Short-Term External Environment Changes, Institutions Remain Optimistic About Long-Term Industry Development Trends

Stock News
·
Oct 14, 2025

Hong Kong Stock Movement | KEYMED BIO-B (02162) Surges Over 5% Intraday as First Dual-Antibody Drug CM336 Initiates Phase III Study

Stock News
·
Sep 22, 2025

Is There Still Potential in Keymed Biosciences After Shares Double in 2025?

Simply Wall St.
·
Sep 14, 2025

Hong Kong Stocks Alert | KEYMED BIO-B (02162) Surges Over 10% in Morning Session on Strong H1 Subcilizumab Commercial Performance and Robust Competitive Position in Atopic Dermatitis Market

Stock News
·
Sep 05, 2025

Bank of Communications International Raises KEYMED BIO-B Target Price to HK$78 as Core Products Accelerate Market Penetration in H1

Stock News
·
Aug 29, 2025

KeyMed Biosciences (02162.HK) Reports Strong Interim 2025 Results With Accelerated Commercialization and Robust R&D Momentum

THOMSON REUTERS
·
Aug 27, 2025

HK Movers | Biotech Stocks Decline, Clover Biopharmaceuticals Drops Over 14%

Tiger Newspress
·
Aug 27, 2025